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Purpose: With respect to various solid cancers, patients with oligometastasis may benefit 
from local therapy. However, this approach is not widely accepted for hepatocellular 
carcinoma. This study investigated the efficacy of local therapy for oligometastatic lesions 
in patients with hepatocellular carcinoma.
Patients and Methods: The study included 69 hepatocellular carcinoma patients present-
ing with oligometastasis to the lung. Characteristics of the patients and treatment options for 
metastatic lesions were reviewed, and a survival analysis was performed. After propensity 
score matching, overall survival and progression-free survival were calculated from the time 
of pulmonary metastasis detection. Factors predicting prognosis were analyzed using 
a multivariate Cox regression analysis.
Results: After propensity score matching, 58 patients with Child-Pugh grade A disease were 
selected. Among them, 22 patients were treated with systemic therapy alone while 36 
patients received local therapy or a combination of local and systemic therapies for meta-
static lesions. Survival rates were higher in patients receiving local therapy than in those 
receiving systemic therapy (2-year overall survival rate, 66.6 vs 31.2%, p<0.001; 2-year 
progression-free survival rate, 47.0 vs 10.6%, p=0.005). In the multivariate Cox regression 
analysis, alpha-fetoprotein levels less than 400 ng/mL and the use of local therapy for 
metastatic lesions were found to be significant favorable prognostic factors.
Conclusion: Local therapy for metastatic lesions improved the oncologic outcomes of 
patients with hepatocellular carcinoma with pulmonary oligometastasis.
Keywords: HCC, local ablation therapy, oligometastasis, propensity score matching
Introduction
The concept of oligometastasis, a transition point between localized disease and 
widespread metastasis, is widely accepted for many types of solid tumors.1 
According to this concept, better outcomes can be anticipated with aggressive 
local intervention, such as surgical resection or radiotherapy for the limited 
metastatic lesions, potentially halting the development of polymetastatic 
disease.2 For decades, hepatic resection for metastatic colorectal cancer has 
been recognized as a standard treatment option; furthermore, local consolidative 
therapy (LCT) for oligometastases from non-small cell lung cancer has shown 
promising results in a randomized Phase II study.3,4 However, for hepatocellular 
carcinoma (HCC), systemic treatment is the standard of care, regardless of 
metastatic status.5,6
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This study intended to answer the question of whether 
the concept of oligometastasis can be applied to HCC. For 
better patient homogeneity, patients presenting with sin-
gle-organ pulmonary oligometastasis were included in this 
study. The lungs were chosen as the site of metastasis 
because pulmonary metastasis is the most frequent type 
of extrahepatic metastasis from HCC, accounting for 
18–55% of cases; furthermore, counting the number of 
pulmonary metastatic lesions using imaging studies is 
easier than counting the number of metastases to other 
organs such as the bone, peritoneum, and lymph 
nodes.7,8 Until now, no studies have completely addressed 
the prognostic factors for oligometastatic HCC and the 
survival benefits from local intervention. In this study, 
we retrospectively analyzed a cohort of HCC patients 
with single-organ pulmonary metastasis to determine 
whether local therapy for metastatic pulmonary lesions 
confers survival benefits. Propensity score matching 
(PSM) analysis was carried out to compensate for biases 
owing to the retrospective nature of the study.
Patients and Methods
Study Population
We identified 624 HCC patients presenting with pulmonary 
metastasis from 2008 to 2015 from the Yonsei Cancer Center 
registry. Among them, 69 patients with 1–4 pulmonary 
metastases were analyzed (Figure 1). We included patients 
regardless of the time of development of pulmonary metas-
tasis; some metastases occurred synchronously while some 
occurred metachronously. We defined synchronous metastasis 
as pulmonary metastasis found within 1 month of diagnosis 
of HCC while others are metachronous. The diagnosis of 
metastasis and its extent was performed based on the results 
of imaging studies on a symptomatic basis: chest computed 
tomography (CT), abdominal CT, whole body bone scan, and 
brain CT/magnetic resonance imaging (MRI). Patients were 
divided into two groups: the STx group (systemic therapy 
alone group) and the LTx group (local therapy group). 
Patients who were treated with a combination of systemic 
agents and local therapy were included in the LTx group.
Figure 1 Flowchart of patient selection.
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Treatment, Response Evaluation, and 
Toxicity
A multidisciplinary team at our institution discussed the 
optimal treatment strategy for advanced HCC and suggested 
local treatments for viable liver tumors and metastatic lesions 
according to a patient’s condition and disease status. 
Metastatic pulmonary lesions were surgically resected 
when complete removal of the metastases seemed possible.
Imaging studies, including abdominal CT and liver MRI, 
were performed every 2–3 months to detect intrahepatic 
lesions. Based on the CT and MRI findings, treatment 
responses were evaluated according to Response Evaluation 
Criteria in Solid Tumors criteria;9 for the evaluation of com-
plete remission in intrahepatic lesions, modified RECIST 
criteria was used.10 In our study, the progression of either 
a viable liver lesion or pulmonary metastasis was considered 
to indicate progressive disease. Metastatic pulmonary lesions 
were evaluated using chest CT every 2–3 months after treat-
ment; 18F-fluorodeoxyglucose positron emission tomogra-
phy-CT was performed according to clinical needs. 
Treatment-related toxicities at the time of follow-up were 
graded according to the Common Terminology Criteria for 
Adverse Events (version 4.03).11
Statistical Analysis and Propensity Score 
Matching
Statistical analyses were performed using SPSS version 23 
(SPSS, Chicago, IL, USA) and R (version 3.6.1; 
R Development Core Team 2009, Vienna, Austria). P-values 
<0.05 were considered significant. The primary endpoint was 
overall survival (OS), defined as the interval from the date of 
diagnosis of pulmonary metastasis to the date of death from 
any cause or to the date of the last visit. Progression-free 
survival (PFS) was calculated from the initiation of local or 
systemic therapy for metastatic lesions to the first detection of 
disease progression on CT or MRI. Patients who died before 
their first radiologic assessment post-treatment were consid-
ered to have progressive disease. The cumulative survival 
probability was calculated using the Kaplan–Meier method, 
and survival curves were compared using the Log rank test. 
Patients lost to follow-up were censored at the date of the last 
visit. To minimize selection bias and the effects of potential 
confounders, patients were matched based on propensity 
scores. PSM analysis was performed using the MatchIt 
package12 in R. Propensity scores were calculated based on 
age, sex, Child-Pugh grade, liver cirrhosis, control of the 
primary liver lesion, serum alpha-fetoprotein (AFP) levels, 
and prothrombin induced by vitamin K absence-II (PIVKA- 
II) levels using a multivariate logistic regression model. 
Patients with the exact same scores (exact score matching 
method) were matched, and non-matched patients were 
excluded. Univariate and multivariate Cox proportional regres-
sion analyses were performed to determine the hazard ratios 
(HRs) for potential prognostic factors.
Results
Patient Characteristics
Patient characteristics at the time of detection of pulmonary 
metastasis are summarized in Table 1. There were 36 patients 
who received local therapy and 33 patients who received 
systemic therapy alone. Male B-viral HCCs were the most 
common. Liver cirrhosis was more frequent in the STx group 
than in the LTx group (75.8 vs 41.2%). In the STx group, one- 
third of patients showed Child-Pugh grade B liver function, 
while all 36 patients in the LTx group showed Child-Pugh 
grade A liver function. PSM was carried out to compensate for 
these differences. After PSM, most features including Child- 
Pugh grade, control of the primary liver lesion, liver cirrhosis, 
and AFP levels were well balanced in the patients.
Treatment and Survival Outcomes After 
PSM
The treatment details for all patients are summarized in 
Table 2. In the LTx group, 16 patients underwent surgical 
resection and 12 patients received radiotherapy for meta-
static lesions. Prescribed radiation doses for metastatic 
pulmonary lesions are as follows; 50 Grays (Gy)/10 frac-
tions (fx) for 6 patients, 50 Gy/5 fx for 3 patients, 60 Gy/4 
fx for 2 patients and 40 Gy/16 fx for 1 patient. Eight 
patients in the LTx group were treated with combination 
therapy (local therapy + systemic therapy).
The median follow-up period was 27 (interquartile range, 
19.0–36.7) months in the LTx group and 23 (interquartile 
range, 14.0–31.3) months in the STx group. The 1-year and 
2-year OS rates were 88.5% and 66.6% in the LTx group and 
63.6% and 31.2% in the STx group, respectively (p<0.001; 
Figure 2A). The 1-year and 2-year PFS rates were 58.9% and 
47.0% in the LTx group and 21.2% and 10.6% in the STx 
group, respectively (p=0.005; Figure 2B). Figure 3 demon-
strates survival curves according to the number of pulmonary 
metastases. Local therapy was found to confer a survival ben-
efit when patients with 2 pulmonary metastases are included in 
the survival analysis (Figure 3A and B). The 2-year OS rate in 
patients with only 1 pulmonary metastasis was 70.7% in the 
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LTx group and 0% in the STx group (p<0.001); the corre-
sponding 2-year PFS rate was 49.7 in the LTx group and 0% in 
the STx group (p=0.009) (Figure 3C and D).
Prognostic Factors Affecting OS and PS 
After PSM (Table 3)
To identify the possible prognostic factors, univariate and 
multivariate analysis were performed for median age (<53 vs 
≥53 years), control of the primary liver lesion (complete 
remission/partial response vs progressive disease), liver cir-
rhosis (yes or no), application of local therapy for metastatic 
lesions (yes or no), and serum levels of AFP (<400 vs ≥400 ng/ 
mL) and PIVKA-II (<200 vs ≥200 mAU/mL). To minimize 
the bias, separate sets of analysis were carried out according to 
the number of pulmonary lesions. Multivariate analysis iden-
tified AFP levels <400 ng/mL and the application of local 
therapy as prognostic factors for a better OS, with HRs of 
4.366 and 3.574, respectively. These factors remained 
Table 1 Patient Characteristics at the Time of Detection of Lung Metastasis Before and After PSM in the LTx and STx Groups
Variables Before PSM After PSM
LTx (n=36) STx (n=33) P-value LTx (n=36) STx (n=22) P-value
Age, years (median, range) 57 (35–75) 51 (34–76) 0.174 57 (35–75) 50 (38–76) 0.136
Sex n, (%) 0.22 0.11
M 29 (80.6) 30 (90.9) 29 (80.6) 21 (95.5)
F 7 (19.4) 3 (9.1) 7 (19.4) 1 (4.5)
HCC etiology 0.104 0.411
B-viral 26 (72.2) 25 (75.8) 26 (72.2) 18 (81.8)
C-viral 2 (5.6) 4 (12.1) 2 (5.6) 2 (9.1)
Others 8 (22.2) 4 (12.1) 8 (22.2) 2 (9.1)
Control of the primary liver lesion, n (%) 0.024 0.304
CR 18 (50.0) 10 (30.3) 18 (50.0) 10 (45.5)
PR 11 (30.6) 5 (15.2) 11 (30.6) 4 (18.2)
SD 0 (0.0) 4 (12.1) 0 (0.0) 0 (0.0)
PD 7 (19.4) 13 (39.4) 7 (19.4) 8 (36.4)
Unevaluable or unknown 0 (0.0) 1 (3.0) 0 (0.0) 0 (0.0)
Liver cirrhosis, n (%) 0.015 0.119
Yes 17 (47.2) 25 (75.8) 17 (47.2) 15 (68.2)
No 19 (52.8) 8 (24.2) 19 (52.8) 7 (31.8)
CP grade, n (%) <0.001 N/A
A 36 (100) 22 (66.7) 36 (100) 22 (100)
B 0 (0.0) 11 (33.3) 0 (0.0) 0 (0.0)
C 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Development time of metastasis, n (%) 0.716 0.581
Synchronous 3 (8.3) 2 (6.1) 3 (8.3) 1 (4.5)
Metachronous 33 (91.7) 31 (93.9) 33 (91.7) 21 (95.5)
Tumor markers


















Time interval between the initial HCC diagnosis 
and extrahepatic metastasis development, months 
(median, range)
23 (0–73) 19 (0–61) 0.042 23 (0–73) 24 (2–61) 0.276
Abbreviations: PSM, propensity score matching; LTx, local therapy; STx, systemic therapy alone; HCC, hepatocellular carcinoma; CR, complete response; PR, partial 
response; SD, stable disease; PD, progressive disease; CP, Child Pugh; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence of antagonist II.
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significant in the analysis of patients with 1 or 2 pulmonary 
lesions. In analysis for PFS, both the application of local 
therapy and AFP levels <400ng/mL were also shown to be 
a significant prognostic factors, with an HR of 3.992 (p=0.018) 
and 2.243 (p=0.036) respectively. Local therapy for metastatic 
lesions remained significant in the analysis of patients with 1 
pulmonary lesion (Supplementary Table 1).
Toxicity
Local therapy-related toxicity was observed in 10 patients 
(27.8%). Complications included esophagitis (n=5), cough 
(n=3), fatigue (n=3), pneumonitis (n=3), nausea and vomit-
ing (n=2), pleural effusion (n=1), and fever (n=1). One 
patient experienced grade 3 pneumonitis with pleural effu-
sion after undergoing surgical removal of the metastatic 
lesions but recovered from the toxicities without lethality. 
After radiation therapy, 2 patients showed grade 2 adverse 
events: 1 patient had grade 2 nausea, vomiting, and cough 
and 1 patient had grade 2 pneumonitis and cough.
During and after systemic therapy, 23 patients (76.7%) 
suffered from treatment related toxicities. Sorafenib 
induced skin and subcutaneous tissue disorders appeared 
in 17 patients of which 12 cases were grade 2 or worse. 
Four patients were ceased to use sorafenib due to skin 
complications.
Thrombocytopenia after cytotoxic chemotherapy was 
observed for 4 patients; 2 patients each for grade 2 and 
grade 3. Other complications were fatigue (n=3), diarrhea 
(n=3), nausea and vomiting (n=2), neutropenia (n=1). All 
grade 1 or 2 toxicities from local therapy and systemic 
therapy were self-limiting.
Discussion/Conclusion
In our study, local therapy for pulmonary metastases from 
HCC improved the patients’ OS and PFS when they had 
1–4 pulmonary metastases. Serum AFP levels <400 ng/mL 
Figure 2 Oncologic outcome in overall survival (A) and progression-free survival (B) according to treatment options for pulmonary metastasis. 
Abbreviations: OS, overall survival; PFS, progression-free survival; STx, systemic therapy alone; LTx, local therapy.
Table 2 Treatment Options for Metastatic Lung Lesions
Treatment Options Number of Patients (%)
Before PSM After PSM
Sorafenib or cytotoxic chemotherapy alone 33 (47.8) 22 (37.9)
Surgery 16 (23.2) 16 (27.6)
Radiotherapy 12 (17.4) 12 (20.7)
Local therapy* + systemic therapy** 8 (11.6) 8 (13.8)
Notes: *Surgery or radiotherapy. **Sorafenib or cytotoxic chemotherapy (5-FU 
+cisplatin, 5-FU+adriamycin+cytoxan, or tegafur + 5-FU). 
Abbreviation: PSM, propensity score matching.
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Figure 3 Subgroup analysis of patients by number of metastasis; overall survival, progression free survival in patients with 1 and 2 metastases (A and B) and within 1 
metastasis (C and D). 
Abbreviations: OS, overall survival; PFS, progression-free survival; STx, systemic therapy alone; LTx, local therapy.
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and the use of local therapy for pulmonary metastases 
were significant favorable prognostic factors for OS and 
PFS. Only 3 patients experienced grade 2 or worse toxi-
cities in relation to surgical resection or radiotherapy for 
the pulmonary lesions, without any lethal side effects.
Oligometastasis is a distinctive state of cancer spread, 
and it has been recognized that local ablative therapies, 
such as radiotherapy and surgical resection, can be cura-
tive options for oligometastatic lesions in various types of 
solid malignancies. For colorectal cancer, hepatic metasta-
sectomy with curative intent resulted in 10-year survival 
rates of 20%–26%. Local therapy for oligometastases from 
non-small cell lung cancer increased the time to the 
appearance of new lesions (median duration: 11.9 months 
in the local therapy group vs 5.7 months in the mainte-
nance systemic treatment/observation group).3,4 However, 
for HCC, only a few studies have reported favorable 
treatment results after metastasectomy for oligometastases 
(Table 4).13–18 The major limitation of those studies was 
selection bias, resulting from the small number of patients 
and retrospective study design. Additionally, it is still 
unclear whether local therapy is a preferable method for 
dealing with oligometastatic HCC as no studies exist when 
oligometastatic HCC is treated with systemic therapy 
alone. To the best of our knowledge, this is the first 
oligometastatic HCC-related study to involve the follow-
ing aspects: first, selection bias was compensated through 
PSM; and second, this study reported favorable treatment 
Table 3 Prognostic Factors for Overall Survival and Progression-Free Survival After PSM (n=58)
Overall Survival Univariate Analysis Multivariate Analysis
HR 95% CI P-value HR 95% CI P-value
Age (<53 vs ≥53 years) 0.914 0.411–2.032 0.825 1.449 0.614–3.420 0.507
Control of the primary liver lesion (CR/PR vs PD) 1.633 0.747–3.568 0.219 0.836 0.358–1.951 0.615
Liver cirrhosis (yes or no) 0.644 0.326–1.272 0.205 0.517 0.226–1.187 0.428
Application of local therapy for metastatic lesions 3.563 1.734–7.322 0.001 3.574 1.703–7.502 0.001
AFP (<400 vs ≥400 ng/mL) 4.027 1.969–8.237 <0.001 4.366 2.058–9.265 <0.001
PIVKA II (<200 vs ≥200 mAU/mL) 0.918 0.456–1.849 0.812 0.441 0.189–1.031 0.157
Progression-Free Survival Univariate Analysis Multivariate Analysis
HR 95% CI P-value HR 95% CI P-value
Age (<53 vs ≥53 years) 0.622 0.282–1.374 0.240 0.627 0.104–3.764 0.233
Control of the primary liver lesion (CR/PR vs PD) 1.149 0.534–2.471 0.722 0.629 0.085–4.659 0.864
Liver cirrhosis (yes or no) 0.647 0.329–1.274 0.208 0.897 0.243–3.312 0.902
Application of local therapy for metastatic lesions 2.531 1.290–4.964 0.007 3.992 1.266–12.595 0.018
AFP (<400 vs ≥400 ng/mL) 2.806 1.368–5.758 0.005 2.243 1.055–4.767 0.036
PIVKA II (<200 vs ≥200 mAU/mL) 1.104 0.549–2.223 0.781 0.318 0.048–2.086 0.954
Abbreviations: PSM, propensity score matching; CR, complete response; PR, partial response; PD, progressive disease; AFP, alpha-fetoprotein; PIVKA-II, protein induced by 
Vitamin K absence of antagonist II; HR, hazard ratio; CI, confidence interval.
Table 4 Studies Reporting the Outcomes of Metastasectomy for Oligometastatic Hepatocellular Carcinoma

















Zhu [13] 2013 18 Resection (100%) Lung Resection (100%) NR 1 (100%) 5-yr: 61.1
Chen [14] 2008 12 Resection (83%)/ 
Transplantation (17%)
Lung Resection (100%) 12 1 (75%)/2 (25%) 5-yr: 30
Tomimaru [15] 2006 8 Resection (100%) Lung Resection (100%) 32 1 (50%)/2 (50%) 5-yr: 58
Lam [16] 1998 9 NR Lung Resection (100%) NR 1 (100%) 5-yr: 67
Kobayashi [17] 2011 18 NR Regional lymph node Resection (100%) 36 1 (100%) Median: 29
Park [18] 2007 5 Resection/TACE/ 
Chemotherapy
Adrenal gland Resection (100%) NR 1 (100%) Median: 21
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results with local therapy compared to those with systemic 
therapy alone.
One hypothesis that explains the better treatment 
results in patients with oligometastases has been reported. 
In 2018, Weichselbaum commented that oligometastatic 
status might be defined not only by the number of metas-
tases but also by the overall tumor burden, time to metas-
tasis, pace of tumor progression, molecular composition of 
the tumor, and host response to metastasis.19 In colorectal 
cancer, the oligometastatic profile depends on biological 
drivers such as microRNAs rather than the disease status 
at diagnosis or therapeutic interventions.20 Signature pat-
terns of microRNAs are potential markers in non-small- 
cell lung carcinomas that can be used to distinguish the 
prognosis of patients, even though molecular evidence of 
oligometastasis in non-small-cell lung carcinomas is not 
well understood.21 However, it is difficult to find studies 
about oligometastatic biomarkers, genetic or clinical prog-
nostic factors, and the relations between molecular char-
acteristics and treatment outcomes with respect to HCC 
oligometastasis.
One of the barriers that further restricts clinical or 
genetic research on extrahepatic oligometastasis is the 
relative difficulty in controlling the primary cancer. As 
most patients with advanced HCC die from liver failure 
rather than from the progression of extrahepatic metasta-
sis, control of the primary lesion can be a vital issue in 
oligometastatic HCC. Liver-directed regional therapies, 
such as transarterial chemoembolization, have been 
reported to prolong the OS of unresectable HCC patients 
in some studies; however, the potential benefits of these 
therapies are still controversial with respect to extrahepatic 
metastasis. According to a study on the Surveillance, 
Epidemiology, and End Results database, 151 patients 
received liver-directed local treatment among 2529 
patients, and the OS and cancer-specific survival were 
longer in the liver-directed local therapy group 
(p<0.0001).22 The only factor related with better survival 
was the use of local therapy. Meanwhile, several studies 
have also reported that the use of transarterial chemoem-
bolization or other aggressive liver-directed therapies is 
not an independent favorable prognostic factor.23,24 In 
our study, liver-directed local therapy after the diagnosis 
of pulmonary metastasis seemed to be beneficial for the 
patients’ survival. Among 30 patients with viable liver 
tumors, 20 received liver-directed therapy, and the 1-year 
and 2-year OS rates were 74.0% and 54.6%, respectively. 
Those who did not receive liver-directed local therapy 
showed 1-year and 2-year OS rates of 50.0% and 20%, 
respectively (p=0.074). In terms of tumor burden as one of 
the factors affecting the state of oligometastasis, liver- 
directed regional therapies could reduce the overall 
tumor burden and prolong the OS of oligometastatic 
HCC patients.
The prognostic factors in patients with extrahepatic 
metastasis vary across studies. Japanese groups have 
reported that the presence of an intrahepatic viable lesion 
and lower performance scores25 or Child-Pugh grade B or 
C, a neutrophil-lymphocyte ratio over 4.0, increased white 
blood cell count, and advanced primary tumor stage (T4)26 
were independent prognostic factors. However, the avail-
able data are extremely rare with respect to single-organ 
oligometastasis. An AFP level ≥400 ng/mL was 
a predictive factor of worse OS in our study. Although 
the prognostic cut-off value for AFP has not been standar-
dized, an elevated AFP level is an established worse 
prognostic factor for post-LTx outcomes,27 OS rates,28–30 
recurrence-free survival rates,31,32 and an increased prob-
ability of extrahepatic recurrence.33 As elevated AFP 
levels increase the likelihood of recurrence, we suggest 
that a hidden tumor burden might exist in dormancy even 
after complete removal of the radiologically visible cancer, 
which is not detected on CT or MRI. The invisible tumors 
cause metastatic cascades after activation with making 
genetic variances, spreading malignant cells in multiple 
intra-extrahepatic sites. This mechanism is consistent 
with our finding that the median OS was only 10 months 
in patients with AFP levels ≥400 ng/mL. The second 
prognostic factor in our study was the application of 
local therapy for metastatic lesions. A large sub-group of 
the LTx group drew our attention. Among the 36 patients 
in the LTx group, 28 patients (over 77%) were treated with 
surgery or radiotherapy for metastatic lesions as the first- 
line therapy; the 1-year and 2-year PFS rates for the 28 
patients were 62.0% and 54.3%, respectively. Among 14 
patients who had no viable liver lesions, the 5-year survi-
val rate was 57.1%, and 6 patients did not experience any 
recurrence without further treatment. In the same context, 
one Korean group reported that pulmonary metastasect-
omy after LTx resulted in significantly higher 2-year and 
5-year survival rates compared to those in the non- 
metastasectomy group (30.6 vs 0%, p=0.007; and 44.7 vs 
12.8%, p=0.017, respectively) with tolerable toxicities. 
Among 23 patients who were treated with pulmonary 
metastasectomy, combined therapy with sorafenib was 
administered to only 4 patients.34
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There are some limitations to our study. Firstly, the 
sample sizes for the LTx and STx groups were relatively 
small. Since the number of patients sets which can be an 
issue for statistical power and appropriateness of analyzing 
method was small, subgroup analysis according to possible 
prognostic factors such as treatment method of primary 
liver cancer was not available. Randomized prospective 
studies are required to compensate additional biases and 
confounders which may derive from each patient’s 
detailed characteristics. Second, there may be inconsisten-
cies in the therapies used, and some of these therapies 
could have been old-fashioned owing to the long period 
of patient enrollment. Third, the results should be 
reviewed with caution as this is a retrospective analysis.
In conclusion, this study showed that local therapy 
improved the oncologic outcomes of patients with a limited 
number of lung metastases, particularly those with good liver 
function and AFP levels less than 400 ng/mL. Further studies 
with a larger number of patients and homogenous treatment 
modalities are needed to support our data.
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